drugset / Trial / NCT02401373

A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.

NCT02401373 ↗

Non-randomizedSingle-groupOpen-labelPrevention

Summary

This is a single center, open, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an investigational Ad5-EBOV vaccine in Healthy Adult Africans aged between 18-60 years in China.

Timeline

Start
2015-03
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad5-EBOV Vaccine — Intramuscular